On December 18, 2016, Lombard Medical, Inc. entered into an investment agreement with MicroPort NeuroTech Corp. and MicroPort NeuroTech CHINA Corp. LIMITED. In accordance with the terms of the investment agreement, the following ceased to be directors of the company effective with the closing of the transaction: Mr. Simon Hubbert (as class III director), Mr. Timothy Haines (as class I director) and Mr. David Milne (as class II director). Further, Mr. John Rush was reclassified from a class II director to a class I director with his term expiring at the 2018 annual meeting of the shareholders of the company. The Board of Directors of the company at its meeting held on December 14, 2016 appointed the following directors to fill the casual vacancies created effective upon the closing of the transaction, and reclassification of Mr. Rush's term: Mr. Jonathan Chen and Mr. HongBin Sun as a class II directors with a term expiring at the 2019 annual meeting of the shareholders of the company.